These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19208592)

  • 1. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases.
    Cella G; Vianello F; Cozzi F; Marotta H; Tona F; Saggiorato G; Iqbal O; Fareed J
    J Rheumatol; 2009 Apr; 36(4):760-7. PubMed ID: 19208592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
    Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with pulmonary hypertension related to congenital systemic-to-pulmonary shunts are characterized by inflammation involving endothelial cell activation and platelet-mediated inflammation.
    Brun H; Holmstrøm H; Thaulow E; Damås JK; Yndestad A; Aukrust P; Ueland T
    Congenit Heart Dis; 2009; 4(3):153-9. PubMed ID: 19489942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases].
    Marotta H; Montisci R; Tiso F; Pontarollo S; Rizzo M; Tona F; Iliceto S; Cozzi F
    Reumatismo; 2007; 59(4):299-303. PubMed ID: 18157286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K; Jakrapanichakul D; Sompradikul S
    J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.
    Langleben D; Orfanos SE; Giovinazzo M; Hirsch A; Baron M; Senécal JL; Armaganidis A; Catravas JD
    Arthritis Rheum; 2008 Apr; 58(4):1156-64. PubMed ID: 18383374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan.
    Vizza CD; Letizia C; Badagliacca R; Poscia R; Pezzuto B; Gambardella C; Nona A; Papa S; Marcon S; Mancone M; Iacoboni C; Riccieri V; Volterrani M; Fedele F
    Int J Cardiol; 2013 Jul; 167(1):220-4. PubMed ID: 22265324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
    Valerio CJ; Handler CE; Kabunga P; Smith CJ; Denton CP; Coghlan JG
    Rheumatology (Oxford); 2010 Nov; 49(11):2147-53. PubMed ID: 20675359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
    D'Alto M; Romeo E; Argiento P; D'Andrea A; Sarubbi B; Correra A; Scognamiglio G; Papa S; Bossone E; Calabrò R; Vizza CD; Russo MG
    Int J Cardiol; 2013 Apr; 164(3):323-6. PubMed ID: 21802156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
    Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
    J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells.
    Damås JK; Otterdal K; Yndestad A; Aass H; Solum NO; Frøland SS; Simonsen S; Aukrust P; Andreassen AK
    Circulation; 2004 Aug; 110(8):999-1005. PubMed ID: 15302794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.
    Karavolias GK; Georgiadou P; Gkouziouta A; Kariofillis P; Karabela G; Tsiapras D; Sbarouni E; Chaidaroglou A; Degiannis D; Adamopoulos S; Voudris V
    Expert Opin Ther Targets; 2010 Dec; 14(12):1283-9. PubMed ID: 20958219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
    Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
    Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil KD; Celermajer DS
    Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.
    Hiramoto Y; Shioyama W; Higuchi K; Arita Y; Kuroda T; Sakata Y; Nakaoka Y; Fujio Y; Yamauchi-Takihara K
    J Cardiol; 2009 Jun; 53(3):374-80. PubMed ID: 19477379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
    Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension.
    Souza R; Jardim C; Martins B; Cortopassi F; Yaksic M; Rabelo R; Bogossian H
    Curr Med Res Opin; 2005 Jun; 21(6):907-11. PubMed ID: 15969891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.